Pathogen Specific Immunity in Patients With Sarcoidosis

Pathogen Specific Immunity in Sarcoidosis

The purpose of this study is to assess the lung cells of healthy volunteers and patients with stage II and III pulmonary sarcoidosis for pathogen specific memory immunity and gene expression patterns.

Study Overview

• Status: Completed
• Conditions: Sarcoidosis
• Intervention / Treatment: Procedure: Bronchoalveolar Lavage and Venipuncture

Detailed Description

BACKGROUND:

Since its initial description 125 years ago, sarcoidosis continues to be a "challenging" disease. Its etiology remains unknown. Discovering the etiology of sarcoidosis remains a major goal with important implications regarding treatment, predicting outcome, as well as determining approaches for preventive measures. Immunological responses and granulomatous tissue formation characterizing sarcoidosis are similar to those observed in a variety of infectious diseases. However, the nature of the specific antigen(s), which putatively trigger the inflammatory response in sarcoidosis, remains elusive. Occurrence of sarcoidosis in spatially related clusters, and household and health care settings strongly support person-to-person transmission of an infectious agent as one of the potential causes of this disease. Sarcoidosis has been associated with a variety of infectious agents, none of which can be cultured. Propionibacterium acnes (P. acnes) and M.tuberculosis (Mtb) are the most commonly identifiable infectious pathogens by PCR-based methods and considered to be associated with the development of this disease. Immunological studies in sarcoidosis have focused largely on the assessment of constitutive, immune responses and the description of the phenotypes of blood and lung cells in patients and control subjects.

DESIGN NARRATIVE:

This study will utilize memory immune responses as search tools for the 'immunological imprints' from P. acnes or Mtb exposure. Peripheral blood mononuclear cells and bronchoalveolar cells will be compared from patients with stage II and/or stage III sarcoidosis and from healthy control subjects. Investigators will use ELISPOT assay to study: (1) frequencies of pathogen-specific interferon-7 and interleukin-10-producing cells, and (2) utilizing P. acnes- or Mtb-infected autologous monocytes and alveolar macrophages as target cell frequencies of pathogen-specific granzyme B-releasing cytotoxic T lymphocytes and natural killer cells. Finally, investigators will test the feasibility of identifying by DNA micro array, pathogen specific, transcriptional host gene expression profiles in P. acnes- and Mtb-stimulated blood cells from healthy control subjects and patients with active sarcoidosis and to compare these with gene expression profiles from autologous, unstimulated in situ lung cells. The studies will address the role of P. acnes and Mtb in the etiology of sarcoidosis and will also serve as a basis or model for future work involving other possible infectious or non-infectious pathogens/antigens for the development of sarcoidosis.

• Study Type: Observational
• Enrollment (Actual): 5

Contacts and Locations

Study Locations

• United States
  • New Jersey
    • Newark, New Jersey, United States, 07103
      • University of Medicine and Dentistry of New Jersey

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 65 years (Adult, Older Adult)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: All

• Sampling Method: Probability Sample

Study Population

Sarcoidosis patients and healthy subjects

Description

Inclusion Criteria for Sarcoidosis Participants:

• Clinical and radiographic signs and symptoms consistent with pulmonary sarcoidosis stage II or III and confirmed histopathology
• No prior corticosteroid or immune suppressive or immune modulating therapies

Inclusion Criteria for Healthy Participants:

• No clinical and radiographic signs and symptoms of respiratory or other chronic or systemic illness

Exclusion Criteria for All Participants:

• Unwilling or unable to provide informed consent
• Unwilling or unable to comply with all study requirements
• History of upper or lower respiratory tract infection within 1 month of study entry
• History of major occupational or microbial exposures known to be associated with granulomatous inflammatory responses
• Positive HIV-1 serology
• Severe psychiatric disease
• Cough-induced syncope
• History of massive hemoptysis or history of pneumothorax, tuberculosis, and immunosuppressive therapies
• Presence of any chronic medical condition requiring daily medication
• Gingivitis or other infectious processes in the oral cavity
• Positive skin test to purified protein derivative (tuberculin)
• Hemoglobin level less than 10g/dl
• Illicit drug use or history of cigarette smoking within 1 year prior to study entry

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Pathogen Specific Immunity in Sarcoidosis	Toxicity, DEP-Induced Cytokines, Effect of DEP on Stimulant-Induced Cytokine Production, in vitro Effects of DEP on M.tb-induced Cytokine Production, time kinetics of In vitro effects of DEP on M.tb-induced cytokine production, effect of DEP Exposure on M.tb H37Ra-induced Lymphocyte Proliferation, whole blood killing experiments	July 2004 - June 2008

Collaborators and Investigators

• Sponsor: University of Medicine and Dentistry of New Jersey
• Collaborators: National Heart, Lung, and Blood Institute (NHLBI)
• Investigators: Principal Investigator: Stephan Schwander, MD, PhD, University of Medicine and Dentistry of New Jersey

Study record dates

Study Major Dates

• Study Start: July 1, 2004
• Primary Completion (Actual): June 1, 2008
• Study Completion (Actual): June 1, 2008

Study Registration Dates

• First Submitted: September 19, 2005
• First Submitted That Met QC Criteria: September 19, 2005
• First Posted (Estimate): September 22, 2005

Study Record Updates

• Last Update Posted (Estimate): December 24, 2013
• Last Update Submitted That Met QC Criteria: December 23, 2013
• Last Verified: December 1, 2013

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Lymphoproliferative Disorders; Lymphatic Diseases; Sarcoidosis; Molecular Mechanisms of Pharmacological Action; Chelating Agents; Sequestering Agents; Dimercaprol
• Other Study ID Numbers: 0120040230; M-230-2004; 287; R21HL077462-02 (U.S. NIH Grant/Contract); R21HL077462 (U.S. NIH Grant/Contract)